Clinical Trial

Specified Drug-Use Survey on Vedolizumab for IV Infusion 300 mg [Crohn's Disease]

Completed
View on ClinicalTrials.gov →
Summary
The purpose of this survey is to evaluate the long-term safety and effectiveness of vedolizumab for intravenous (IV) infusion 300 milligrams (mg) in Crohn's disease (CD) patients in the routine clinical setting.
Protocol Amendment History 3 changes
critical Trial completed 2026-07-07
notable Primary completion moved earlier: 2026-06-30 -> 2026-03-25 2026-07-07
minor Completion moved earlier: 2026-06-30 -> 2026-03-25 2026-07-07
Trial Details
NCT Number NCT04002180
Lead Sponsor Takeda
Conditions Crohn's Disease
Enrollment 335 participants
Start Date 2019-07-01
Primary Completion 2026-03-25 (estimated)
Study Completion 2026-03-25 (estimated)
Updated on ClinicalTrials.gov 2026-07-06